Literature DB >> 17604367

Exacerbation of ulcerative colitis after rituximab salvage therapy.

Martin Goetz1, Raja Atreya, Maryam Ghalibafian, Peter R Galle, Markus F Neurath.   

Abstract

BACKGROUND: B-cells are considered to play a pathogenic role in human ulcerative colitis (UC) by producing autoantibodies that cause epithelial cell damage. Here we report on a patient with intractable UC who suffered from a severe exacerbation of UC after salvage therapy with rituximab, a B-cell-depleting anti-CD20-antibody.
METHODS: A 58-year-old patient with active long-standing UC and unresponsiveness or adverse events to mesalamine, corticosteroids, azathioprine, methotrexate, infliximab, leukapheresis, mycophenolate mofetil, and adalimumab received 375 mg/m(2) rituximab.
RESULTS: A severe exacerbation of UC activity was noted upon therapy that required hospitalization. Subsequent studies showed a complete depletion of CD20-positive mucosal B-cells associated with a suppression of local IL-10 production.
CONCLUSIONS: In contrast to rheumatoid arthritis patients, rituximab had deleterious effects in our UC patient by blocking IL-10 producing B-cells. Our data suggest an important anti- rather than proinflammatory role of B-cells in UC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604367     DOI: 10.1002/ibd.20215

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  73 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  Crohn disease: a current perspective on genetics, autophagy and immunity.

Authors:  Thaddeus S Stappenbeck; John D Rioux; Atsushi Mizoguchi; Tatsuya Saitoh; Alan Huett; Arlette Darfeuille-Michaud; Tom Wileman; Noboru Mizushima; Simon Carding; Shizuo Akira; Miles Parkes; Ramnik J Xavier
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

3.  Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection.

Authors:  Vishal Sindhava; Michael E Woodman; Brian Stevenson; Subbarao Bondada
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 4.  Animal models of IBD: linkage to human disease.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Curr Opin Pharmacol       Date:  2010-06-08       Impact factor: 5.547

5.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 6.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

Review 7.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

Review 8.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

Review 9.  Role of cytokines in inflammatory bowel disease.

Authors:  Fausto Sanchez-Munoz; Aaron Dominguez-Lopez; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 10.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.